Literature DB >> 17081089

Percutaneous closure of ventricular septal defects.

Gianfranco Butera1, Massimo Chessa, Luciane Piazza, Diana Negura, Angelo Micheletti, Mario Carminati.   

Abstract

Isolated ventricular septal defect is the most common form of congenital heart disease. Surgery has been performed for many years and is considered the gold standard for the treatment of ventricular septal defects. However, it is associated with morbidity and mortality. Less invasive techniques have been developed and currently percutaneous closure of muscular and perimembranous ventricular septal defects has to be considered a possible alternative to the standard surgical approach.

Entities:  

Mesh:

Year:  2006        PMID: 17081089     DOI: 10.1586/14779072.4.5.671

Source DB:  PubMed          Journal:  Expert Rev Cardiovasc Ther        ISSN: 1477-9072


  4 in total

1.  Follow-up of patients with interventional closure of ventricular septal defects with Amplatzer Duct Occluder II.

Authors:  M Kanaan; P Ewert; F Berger; S Assa; S Schubert
Journal:  Pediatr Cardiol       Date:  2014-09-02       Impact factor: 1.655

2.  Changes in serum natriuretic peptide levels after percutaneous closure of small to moderate ventricular septal defects.

Authors:  Yuksel Kaya; Ramazan Akdemir; Huseyin Gunduz; Sani Murat; Orhan Bulut; Ibrahim Kocayigit; M Bulent Vatan; M Akif Cakar; Ekrem Yeter; Harun Kilic; Mustafa Tarik Agac; Zeydin Acar
Journal:  ScientificWorldJournal       Date:  2012-04-26

3.  A new scoring system for spontaneous closure prediction of perimembranous ventricular septal defects in children.

Authors:  Jing Sun; Kun Sun; Sun Chen; Liping Yao; Yuqi Zhang
Journal:  PLoS One       Date:  2014-12-05       Impact factor: 3.240

4.  Short- and medium-term follow-up of transcatheter closure of perimembranous ventricular septal defects.

Authors:  Hao Li; Youyang Shi; Songyue Zhang; Yue Ren; Xing Rong; Zhenquan Wang; Tianhe Xia; Tingting Wu; Haitang Xu; Yaoyao Yan; Yi Zhan; Maoping Chu; Rongzhou Wu
Journal:  BMC Cardiovasc Disord       Date:  2019-10-16       Impact factor: 2.298

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.